CAPR Class Action Alert: Capricor Therapeutics Clinical Data Issues and Subsequent 64% Stock Drop Lead to Investor Securities Fraud Class Action to Recover Losses

Capricor Therapeutics was sued for securities fraud over alleged misstatements related to Deramiocel and clinical data used in its Biologics License Application, contributing to a 64% stock drop. The claim centers on the integrity of the clinical dataset underpinning the BLA. The legal overhang is likely to pressure investor confidence and valuation in the near term.